.... and not only that, Montrachet, the effectiveness of the...

  1. 8,392 Posts.
    lightbulb Created with Sketch. 3686
    .... and not only that, Montrachet, the effectiveness of the combination in late stage sufferers (those previously given up as dead) is 83%.

    And, there is yet another upside.... Grade 3 or higher treatment related adverse events is 10.1% in Keytruda alone, BUT is reduced to ZERO when combined with Cavatak!

    It should make Cavatak worth heaps (imho)... heaps. Wake up market... and wake up Merck!
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.